Regeneron Pharmaceuticals (NASDAQ:REGN) Trading Down 2.6%

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)’s share price traded down 2.6% on Thursday . The stock traded as low as $909.80 and last traded at $911.41. 52,408 shares changed hands during mid-day trading, a decline of 89% from the average session volume of 481,136 shares. The stock had previously closed at $936.20.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. Morgan Stanley upped their price target on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an “overweight” rating in a report on Wednesday, March 13th. Royal Bank of Canada reiterated an “outperform” rating and issued a $1,189.00 price target on shares of Regeneron Pharmaceuticals in a report on Tuesday. Truist Financial restated a “buy” rating and set a $1,135.00 target price on shares of Regeneron Pharmaceuticals in a report on Wednesday, April 3rd. Cantor Fitzgerald increased their target price on shares of Regeneron Pharmaceuticals from $850.00 to $925.00 and gave the stock a “neutral” rating in a report on Tuesday, February 6th. Finally, Bank of America increased their target price on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the stock an “underperform” rating in a report on Friday. One research analyst has rated the stock with a sell rating, four have issued a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $970.57.

Regeneron Pharmaceuticals Price Performance

The company has a market capitalization of $99.30 billion, a P/E ratio of 26.03, a price-to-earnings-growth ratio of 2.69 and a beta of 0.11. The company’s 50-day moving average price is $957.56 and its two-hundred day moving average price is $888.71. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.69 and a quick ratio of 4.94.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share for the quarter, beating the consensus estimate of $10.73 by $1.13. The company had revenue of $3.43 billion for the quarter, compared to analyst estimates of $3.29 billion. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The company’s revenue was up .6% on a year-over-year basis. During the same period in the prior year, the firm earned $10.96 earnings per share. As a group, sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 38.18 EPS for the current year.

Insider Activity

In other news, Director Bonnie L. Bassler sold 827 shares of the stock in a transaction dated Tuesday, January 30th. The shares were sold at an average price of $959.00, for a total value of $793,093.00. Following the transaction, the director now directly owns 1,382 shares of the company’s stock, valued at $1,325,338. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Bonnie L. Bassler sold 827 shares of the firm’s stock in a transaction dated Tuesday, January 30th. The shares were sold at an average price of $959.00, for a total transaction of $793,093.00. Following the transaction, the director now directly owns 1,382 shares of the company’s stock, valued at $1,325,338. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $954.22, for a total transaction of $95,422.00. Following the transaction, the director now directly owns 18,382 shares in the company, valued at $17,540,472.04. The disclosure for this sale can be found here. Insiders have sold 13,729 shares of company stock valued at $13,124,641 over the last ninety days. 8.83% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

A number of hedge funds have recently bought and sold shares of REGN. Sunbelt Securities Inc. bought a new position in Regeneron Pharmaceuticals during the first quarter worth about $25,000. Annis Gardner Whiting Capital Advisors LLC acquired a new stake in Regeneron Pharmaceuticals during the third quarter worth about $26,000. O Dell Group LLC acquired a new stake in Regeneron Pharmaceuticals during the fourth quarter worth about $27,000. Fortitude Family Office LLC acquired a new stake in Regeneron Pharmaceuticals during the fourth quarter worth about $31,000. Finally, MCF Advisors LLC grew its stake in Regeneron Pharmaceuticals by 50.0% during the fourth quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 12 shares in the last quarter. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.